Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTERPRET: Vedolizumab Dose Optimization in UC
NCT03029143Phase 4Completed
- Sponsor
- Takeda
- Start
- Mar 2017
- Primary completion
- Oct 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of vedolizumab in ulcerative colitis (UC), sponsored by Takeda. Started Mar 2017; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03029143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029143.